Could Azurrx Biopharma Incorporated (NASDAQ:AZRX) Skyrocket? The Stock Had Too Little Sellers

December 8, 2017 - By Lynda A. Deweese

 Could Azurrx Biopharma Incorporated (NASDAQ:AZRX) Skyrocket? The Stock Had Too Little Sellers

The stock of Azurrx Biopharma Incorporated (NASDAQ:AZRX) registered a decrease of 6.12% in short interest. AZRX’s total short interest was 26,100 shares in December as published by FINRA. Its down 6.12% from 27,800 shares, reported previously. With 35,100 shares average volume, it will take short sellers 1 days to cover their AZRX’s short positions. The short interest to Azurrx Biopharma Incorporated’s float is 0.91%.

The stock decreased 1.95% or $0.06 during the last trading session, reaching $3.01. About 21,472 shares traded. AzurRx BioPharma, Inc. (NASDAQ:AZRX) has 0.00% since December 8, 2016 and is . It has underperformed by 16.70% the S&P500.

AzurRx BioPharma, Inc., a clinical development stage biopharmaceutical company, engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company has market cap of $34.78 million. The Company’s product pipeline consists of two therapeutic proteins under development, including MS1819, an autologous yeast recombinant lipase, which is in Phase IIa trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase combination of bacterial origin for the prevention of hospital-acquired infections, as well as antibiotic-associated diarrhea. It currently has negative earnings.

More notable recent AzurRx BioPharma, Inc. (NASDAQ:AZRX) news were published by: Globenewswire.com which released: “WallachBeth Capital Initiates Research Coverage of AzurRx BioPharma” on December 12, 2016, also Globenewswire.com with their article: “AzurRx BioPharma Announces Agreement in Principle with TransChem for MTAN …” published on December 06, 2016, Businesswire.com published: “AzurRx BioPharma Announces Pricing of Initial Public Offering” on October 12, 2016. More interesting news about AzurRx BioPharma, Inc. (NASDAQ:AZRX) were released by: Globenewswire.com and their article: “AzurRx BioPharma to Present at the 2017 Biotech Showcase Conference” published on December 28, 2016 as well as Globenewswire.com‘s news article titled: “AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data …” with publication date: September 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.